High-performance analytical solutions for residual DNA testing in cell and gene therapy using real-time PCR or digital PCR technologies

Cell & Gene Therapy Insights 2024; 1(1), 51

DOI: 10.18609/cgti.2023.011

Published: 10 February
FastFacts
Christina Bouwens


Watch the video or view the poster to:

  • Understand what are the regulatory requirements and challenges in residual host cell DNA testing for cell and gene therapies 
  • Benefit from a technology review—real-time PCR versus digital PCR
  • Receive guidance on selecting the best technology for the intended purpose 
  • Gain insights into an integrated workflow solution to support process development and a GMP environment (E.coli and E1A end-to-end workflow)

Christina Bouwens is a dedicated professional in the field of molecular biology and precision medicine research. Currently serving as the Global Market Development Manager for Digital PCR at Thermo Fisher Scientific, Christina brings a wealth of knowledge and experience in digital PCR assay development. She has made significant contributions to the field, particularly in the area of cancer biology. Christina has authored peer-reviewed publications in the field of oncology, including two first authorships, which focus on personalized circulating tumor DNA detection and monitoring using digital PCR technology.